CL2018002461A1 - Composiciones farmacéuticas disuasivas del abuso. - Google Patents

Composiciones farmacéuticas disuasivas del abuso.

Info

Publication number
CL2018002461A1
CL2018002461A1 CL2018002461A CL2018002461A CL2018002461A1 CL 2018002461 A1 CL2018002461 A1 CL 2018002461A1 CL 2018002461 A CL2018002461 A CL 2018002461A CL 2018002461 A CL2018002461 A CL 2018002461A CL 2018002461 A1 CL2018002461 A1 CL 2018002461A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
deterring abuse
deterring
abuse
lacase
Prior art date
Application number
CL2018002461A
Other languages
English (en)
Inventor
Georg Gübitz
Katrin Greimel
Martin Brandauer
Daniela Huber
Klaus Bleymaier
Wolfgang Kroutil
Doris Lechner
Christof Wachter
Harald Wagner
Heimo Winkler
Original Assignee
G L Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G L Pharma Gmbh filed Critical G L Pharma Gmbh
Publication of CL2018002461A1 publication Critical patent/CL2018002461A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03002—Laccase (1.10.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UN FÁRMACO CON UN GRUPO FUNCIONAL REACTIVO CON LACASA Y UNA LACASA (EC 1.10.3.2) Y MÉTODOS PARA FABRICAR TALES COMPOSICIONES.
CL2018002461A 2016-02-29 2018-08-28 Composiciones farmacéuticas disuasivas del abuso. CL2018002461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16157804.2A EP3231420A1 (en) 2016-02-29 2016-02-29 Abuse-deterrent pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CL2018002461A1 true CL2018002461A1 (es) 2018-10-12

Family

ID=55446693

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002461A CL2018002461A1 (es) 2016-02-29 2018-08-28 Composiciones farmacéuticas disuasivas del abuso.

Country Status (11)

Country Link
US (1) US20190070268A1 (es)
EP (2) EP3231420A1 (es)
JP (1) JP2019507172A (es)
CN (1) CN109195591A (es)
AU (1) AU2017227982A1 (es)
BR (1) BR112018067656A2 (es)
CA (1) CA3014005A1 (es)
CL (1) CL2018002461A1 (es)
ES (1) ES2821699T3 (es)
MX (1) MX2018010434A (es)
WO (1) WO2017148919A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3210596A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
WO2020167566A1 (en) * 2019-02-11 2020-08-20 The Rockefeller University Methods and compositions for the treatment of alcohol use disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852157A (en) 1971-05-14 1974-12-03 Syva Corp Compounds for enzyme amplification assay
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4299916A (en) 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
JPH02238885A (ja) 1989-03-13 1990-09-21 Oji Paper Co Ltd フェノールオキシダーゼ遺伝子組換えｄｎａ、該組換えｄｎａにより形質転換された微生物、その培養物及びフェノールオキシダーゼの製造方法
FI903443A (fi) 1990-07-06 1992-01-07 Valtion Teknillinen Framstaellning av lackas genom rekombinantorganismer.
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
JP3691516B2 (ja) 1994-09-27 2005-09-07 ノボザイムス アクティーゼルスカブ アセトシリンゴンのような増強剤
WO1997027841A1 (en) 1996-01-31 1997-08-07 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
AU2635097A (en) 1996-04-29 1997-11-19 Novo Nordisk A/S Non-aqueous, liquid, enzyme-containing compositions
JP3320307B2 (ja) 1996-06-06 2002-09-03 株式会社エス・ディー・エス バイオテック フェノール性化合物等の高分子化方法及びその利用
GB9622516D0 (en) 1996-10-29 1997-01-08 Univ Cambridge Tech Enzymic cofactor cycling
US6100080A (en) * 1996-12-18 2000-08-08 Novo Nordisk A/S Method for enzymatic treatment of biofilm
DE69903430T2 (de) 1998-07-08 2003-06-05 Novozymes As Verwendung eines phenoloxidierenden enzymes zum behandeln von tabak
JP4727818B2 (ja) 1998-11-09 2011-07-20 ノボザイムス アクティーゼルスカブ オキシドレダクターゼ及びｎ−ヒドロキシアニリド型の増強剤を含む抗微生物組成物
DE10029671A1 (de) 2000-06-23 2002-01-10 Frieder Schauer Biotransformation von biologisch aktiven Verindungen aus verschiedenen chemischen Stoffklassen mittels der Enzyme Laccase und Manganperoxidase
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
EP2422772A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
CN1925865B (zh) * 2003-09-30 2011-09-14 希拉有限责任公司 防止用药过量或滥用的药物组合物
CA2550324A1 (en) 2003-12-30 2005-07-14 Gumlink A/S Chewing gum comprising biodegradable polymers and having accelerated degradability
AU2012201450A1 (en) 2004-11-24 2012-04-05 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
JP4767796B2 (ja) * 2005-09-01 2011-09-07 新田ゼラチン株式会社 菓子に用いるゴム状組成物
DE102006006904A1 (de) * 2006-02-09 2007-08-23 Universität Rostock Neue Mittel zur Blutstillung und Klebstoffe für medizinische Anwendungen
DE602006021637D1 (de) 2006-06-16 2011-06-09 Gumlink As Kaugummi enthaltend eine hydrophobe enzymformulierung
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
CA2671200A1 (en) 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
DE102006048833A1 (de) 2006-10-16 2008-04-17 Universität Rostock Behandlung von Osteoporose
US20110262359A1 (en) * 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
MX2012015187A (es) 2010-07-02 2013-05-09 Procter & Gamble Metodo para suministrar un agente activo.
US20120202838A1 (en) 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
WO2012085016A1 (de) 2010-12-20 2012-06-28 Cytec Austria Gmbh Verfahren zur härtung von oberflächenbeschichtungsmitteln
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
JP2014505736A (ja) 2011-02-17 2014-03-06 キューアールエックスファーマ リミテッド 固体投薬形態の乱用を防止するための技術
CA2827662C (en) * 2011-03-09 2020-07-14 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
AU2012328837B2 (en) * 2011-10-26 2015-07-09 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
JP5922851B2 (ja) 2012-11-30 2016-05-24 アキュラ・ファーマシューティカルズ・インコーポレーテッド 活性医薬成分の自己制御放出
JP6198495B2 (ja) 2013-07-12 2017-09-20 キヤノン株式会社 画像形成装置
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
EP3210596A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition

Also Published As

Publication number Publication date
MX2018010434A (es) 2019-05-22
CA3014005A1 (en) 2017-09-08
BR112018067656A2 (pt) 2019-01-02
US20190070268A1 (en) 2019-03-07
WO2017148919A1 (en) 2017-09-08
AU2017227982A1 (en) 2018-08-23
ES2821699T3 (es) 2021-04-27
EP3423046B1 (en) 2020-08-12
EP3231420A1 (en) 2017-10-18
EP3423046A1 (en) 2019-01-09
JP2019507172A (ja) 2019-03-14
CN109195591A (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
CR20180564A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen
DOP2017000280A (es) Formas administración sólidas de palbociclib
BR112018072539A2 (pt) composições de epinefrina de administração aumentada
IL262751A (en) Pharmaceutical preparations with increased penetration
UY37351A (es) Complemento para el pienso
EA033345B1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
IL291521A (en) An injection device, especially an automatic injector, for the simultaneous administration of several drugs
PH12016501841A1 (en) Immunosuppressant formulation
BR112017013580A2 (pt) combinações de inibidor de btk e regime de dosagem.
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
DK3295993T3 (da) Indretning til administration af et kosmetikprodukt, tilsvarende fremgangsmåde og beholder
CL2018002461A1 (es) Composiciones farmacéuticas disuasivas del abuso.
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
DK3558423T3 (da) Medikamentadministrationsanordning
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
DOP2019000015A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
EA201691924A1 (ru) Фармацевтические композиции
BR112017004552A2 (pt) composições farmacêuticas
CL2018002462A1 (es) Composiciones farmacéuticas disuasivas del abuso.
DK3534998T3 (da) Medikamentadministrationsanordning
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
MX2015013231A (es) Composiciones que disuaden el abuso y metodos de utilizacion.
UA106905U (uk) Фармацевтична композиція